New TB Treatment Combines Two Antibiotics
Published on:
Source: The Hindu
Share this post

Article Summary
Summary of Research on Isoniazid and Vancomycin Combination for Tuberculosis Treatment
Research Institution:
- Indian Institute of Science (IISc), Bengaluru
Key Findings:
- Target Disease: Tuberculosis (TB) caused by Mycobacterium tuberculosis.
- Challenge: Growing resistance to isoniazid, a frontline TB drug.
- New Strategy Identified: Combination treatment using isoniazid and vancomycin is effective against drug-resistant strains.
Details of Study:
- Conducted in the Department of Biochemistry.
- Aim: To reverse isoniazid resistance.
- Method: Tested combination against clinical isolates of M. tuberculosis from patient sputum samples.
- Collaborating Institution: National Tuberculosis Institute, Bengaluru.
Results:
- Combination treatment led to more than 90% reduction in bacterial growth in most tested isolates, including multi-drug resistant (MDR) strains.
- Infected mouse model showed approximately 10-fold reduction in bacterial load in lungs and spleen after 10 days of treatment with the combination, which was not observed with the individual drugs alone.
- Histopathological examination indicated a reduction in lung granulomas with the combination treatment.
Scientific Explanation:
- Isoniazid requires activation by a bacterial enzyme; mutations can cause resistance by blocking its activation pathway.
- Vancomycin struggles to penetrate the cell wall of M. tuberculosis.
- The combination therapy disrupts the wall integrity, allowing vancomycin to kill bacteria effectively.
Next Steps:
- Researchers are working towards advancing this combination therapy for clinical trials.
Implications:
- This research highlights significant advancements in the treatment of drug-resistant TB.
- If successful in clinical trials, this combination could enhance treatment options for patients suffering from resistant TB strains.
Importance in Public Health:
- Tuberculosis remains a significant health challenge globally, making innovative treatments crucial for public health strategies against antibiotic resistance.
Key Terms & Concepts
| Isoniazid | Frontline drug for TB treatment |
| Vancomycin | antibiotic used in combination |
| Mycobacterium tuberculosis | Bacterium causing tuberculosis |
| Indian Institute of Science (IISc) | Conducting the research study |
| National Tuberculosis Institute, Bengaluru | Collaborating on research |
| Microbiology Spectrum | Published the research study |
| Multidrug-resistant (MDR) isolates | Subgroup of bacteria tested |
| 10-fold reduction | Bacterial load reduction observation |
| November 17, 2026 | Publication date of the study |


